Kadomoto Suguru, Yaegashi Hiroshi, Nakashima Kazufumi, Iijima Masashi, Kawaguchi Shohei, Nohara Takahiro, Shigehara Kazuyoshi, Izumi Kouji, Kadono Yoshifumi, Nakajima Kenichi, Mizokami Atsushi
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Department of Radiotherapy, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
Anticancer Res. 2019 May;39(5):2553-2559. doi: 10.21873/anticanres.13377.
BACKGROUND/AIM: This study aimed to evaluate the therapeutic effect of enzalutamide (ENZ) or abiraterone acetate (ABI) on bone metastasis in castration-resistant prostate cancer (CRPC), using bone scan index (BSI).
Treatment outcomes for 31 patients who had undergone ENZ or ABI treatment were examined for CRPC with bone metastases. Cox proportional-hazards regression models were used to investigate the association between overall survival (OS) and clinical characteristics.
Median OS after ENZ or ABI treatment was 29 months. Considering the flare phenomenon, BSI in 17 (55%) patients decreased following treatment. In multivariate analysis, low baseline BSI value and a decrease in BSI following treatment were associated with longer OS (hazard ratio [HR]=8.009; p=0.35 and HR=7.025; p=0.045*, respectively).
Low BSI value before ENZ/ABI treatment and a decrease in BSI following ENZ or ABI treatment are independent predictors of longer OS. BSI could be useful for risk assessment of CRPC patients with bone metastases.
背景/目的：本研究旨在使用骨扫描指数（BSI）评估恩杂鲁胺（ENZ）或醋酸阿比特龙（ABI）对去势抵抗性前列腺癌（CRPC）骨转移的治疗效果。
对31例接受ENZ或ABI治疗的CRPC骨转移患者的治疗结果进行了检查。采用Cox比例风险回归模型研究总生存期（OS）与临床特征之间的关联。
ENZ或ABI治疗后的中位OS为29个月。考虑到flare现象，17例（55%）患者治疗后BSI下降。在多变量分析中，低基线BSI值和治疗后BSI下降与更长的OS相关（风险比[HR]=8.009；p=0.35和HR=7.025；p=0.045*）。
ENZ/ABI治疗前低BSI值以及ENZ或ABI治疗后BSI下降是OS延长的独立预测因素。BSI可用于CRPC骨转移患者的风险评估。
